Nemolike kinase expression predicts poor survival in colorectal cancer

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 1181-1187

  Chen, Jingbo ^a   Han, Yunwei ^b,c   Zhao, Xiaoqian ^d   Yang, Mingyu ^a   Liu, Bo ^a   Xi, Xiangpeng ^a   Xu, Xiaolin ^a   Liang, Tiejun ^d   Xia, Lijian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIVERSITY   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Biomarker; Colorectal cancer; Nemolike kinase; Prognosis; Recurrence

Indexed keywords

NLK PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ADULT; AGED; CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; UP-REGULATION;

EID: 84916222178     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2851     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Gaedcke J, Grade M, Camps J, Skilde R, Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi BM, Mller S, et al: The rectal cancer microRNAome -microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res 18: 4919-4930, 2012.
3. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
4. Zhang S, Cui Y, Weng Z, Gong X, Chen M and Zhong B: Changes on the disease pattern of primary colorectal cancers in Southern China: a retrospective study of 20 years. Int J Colorectal Dis 24: 943-949, 2009.
5. Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin 63: 11-30, 2013.
6. Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ and van der Burg SH: Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines 10: 899-921, 2011.
7. Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO and Lothe RA: Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 21: 820-829, 2003.
8. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-499, 2009.
9. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474, 2010.
10. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934, 2002.
11. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE and Thibodeau SN: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14: 3408-3415, 2008.
12. Anastas JN and Moon RT: WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13: 11-26, 2013.
13. Ishikawa T, Shimizu D, Kito A, Ota I, Sasaki T, Tanabe M, Yamada A, Arioka H, Shimizu S, Wakasugi J, et al: Breast cancer manifested by hematologic disorders. J Thorac Dis 4: 650-654, 2012.
14. Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL and Corey E: Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate 69: 1481-1492, 2009.
15. Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Park WS, Lee JY and Nam SW: Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem 110: 687-696, 2010.
16. Cui G, Li Z, Shao B, Zhao L, Zhou Y, Lu T, Wang J, Shi X, Wang J, Zuo G, et al: Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci 18: 271-275, 2011.
17. Wang S, Wu X, Chen Y, Zhang J, Ding J, Zhou Y, He S, Tan Y, Qiang F, Bai J, et al: Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res 18: 2987-2996, 2012.
18. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148, 2008.
19. Ishitani T and Ishitani S: Nemo-like kinase, a multifaceted cell signaling regulator. Cell Signal 25: 190-197, 2013.
20. Ota S, Ishitani S, Shimizu N, Matsumoto K, Itoh M and Ishitani T: NLK positively regulates Wnt/β-catenin signalling by phosphorylating LEF1 in neural progenitor cells. EMBO J 31: 1904-1915, 2012.
21. Ishitani T: Context-dependent dual and opposite roles of nemo-like kinase in the Wnt/β -catenin signaling. Cell Cycle 11: 1743-1745, 2012.
22. Yasuda J, Yokoo H, Yamada T, Kitabayashi I, Sekiya T and Ichikawa H: Nemo-like kinase suppresses a wide range of transcription factors, including nuclear factor-κB. Cancer Sci 95: 52-57, 2004.
23. Li M, Zhang S, Wang Z, Zhang B, Wu X, Weng H, Ding Q, Tan Z, Zhang N, Mu J, et al: Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol 34: 3995-4000, 2013.